Redsense signs distribution agreement for Singapore with initial evaluation at Singapore General Hospital
Redsense Medical has signed a distribution agreement for Singapore with the Asian distributor Transmedic. An evaluation of the company’s blood leakage alarm for used in connection with hemodialysis is expected to be initiated in Q1 2018 at Singapore’s largest hospital, Singapore General Hospital.
As soon as the product is approved for sale and usage in Singapore, Transmedic will be able to commit to a first order and initiate the evaluation at Singapore General Hospital. The necessary applications for this have been submitted.
“We are excited to be able to establish Redsense in Singapore together with Transmedic. Singapore General Hospital, where the evaluation will take place, and the country’s health care system in general, is characterised by high quality and efficacy which makes our product a great fit,” says Patrik Byhmer, CEO of Redsense Medical.
Transmedic is a Singapore-based company with business operations in seven countries in Southeast Asia that engages in the sales and distribution of medical devices and highly specialized drugs from 40 different companies across hospitals, clinics, and health-centers. In Singapore alone, there are over 120 dialysis centers with over 7 000 patients of which 87 percent receive hemodialys treatments.
Redsense and Transmedic expects the Redsense blood leakage alarm to be able to contribute to a reduced workload for nurses and other staff members in Singapore, in big hospitals with dedicated dialysis wards as well as at really large dialysis centers.
For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 8th of December 2017.